Andrey V. Polynovskiy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrey V. Polynovskiy has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Z. Z. Mamedli
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
12 shared publications - Dmitrii V. Kuzmichev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
9 shared publications - A. A. Aniskin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
5 shared publications - Denis V. Aleksantsev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
5 shared publications - Alexey A. Tryakin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications - Olesya A. Kuznetsova
National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, Russia; OncoAtlas LCC, 119049 Moscow, Russia
4 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 13 (3) , 80-91
Clonal hematopoiesis of indeterminate potential in metastatic colorectal cancer: bidirectional regulation, systemic selection, and translational strategies
Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition characterized by the expansion of hematopoietic stem cells harboring somatic mutations in the absence of overt hematological malignancies. Traditionally, CHIP has been viewed either as a driver of systemic inflammation or as a source of false-positive artifacts in liquid biopsy assays for solid tumors. This review systematizes the evidence for a reciprocal pathogenetic link – namely, the distant regulatory influence of metastatic colorectal cancer (mCRC) on the bone marrow microenvironment. We propose a conceptual model of a bidirectional “mCRC ↔ CHIP” interface, delineate the molecular mechanisms governing mutant clone selection under tumor-imposed pressure, and outline strategies to minimize diagnostic errors in circulating tumor DNA analysis. Metastatic colorectal cancer acts as a systemic regulator of hematopoiesis. Chronic systemic inflammation induced by the secretion of tumor and metastasis mediators (interleukin (IL) 6, tumor necrosis factor α, granulocyte colony-stimulating factor), in combination with persistent oxidative stress, causes replicative exhaustion and apoptosis of normal hematopoietic stem cells. Under these conditions, CHIP clones carrying mutations in genes involved in epigenetic control (TET2, DNMT3A) and DNA damage response (TP53, PPM1D) acquire a selective fitness advantage. In the context of bidirectional regulation, hyperreactive myeloid cells originating from CHIP clones migrate to intestinal and hepatic tissues, where they establish pre-metastatic niches, promote angiogenesis (via vascular endothelial growth factor, matrix metallopeptidase 9), and suppress CD8+ T-cell activity (through programmed death ligand 1, indoleamine-2,3-dioxygenase). Standard platinum-based chemotherapy (FOLFOX) acts as an additional catalyst for the iatrogenic selection of TP53/PPM1D clones, whereas primary tumor resection de-escalates the inflammatory pressure on the bone marrow. CHIP compromises the specificity of liquid biopsy by generating false-positive signals for progression (TP53) and resistance (RAS) markers. The gold standard for overcoming this interference is paired buffy coat sequencing combined with fragmentomics-based approaches. Disruption of the pathological “mCRC ↔ CHIP” axis through anti-cytokine therapy (IL-1β and IL-6 inhibitors) and the integration of onco-hematological monitoring into precision oncology may prevent tumor immune evasion, reduce the risk of secondary leukemias, and improve patient survival outcomes.
- 18 September 2026
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 13 (3) , 80-91
Open AccessClonal hematopoiesis of indeterminate potential in metastatic colorectal cancer: bidirectional regulation, systemic selection, and translational strategies
Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition characterized by the expansion of hematopoietic stem cells harboring somatic mutations in the absence of overt hematological malignancies. Traditionally, CHIP has been viewed either as a driver of systemic inflammation or as a source of false-positive artifacts in liquid biopsy assays for solid tumors. This review systematizes the evidence for a reciprocal pathogenetic link – namely, the distant regulatory influence of metastatic colorectal cancer (mCRC) on the bone marrow microenvironment. We propose a conceptual model of a bidirectional “mCRC ↔ CHIP” interface, delineate the molecular mechanisms governing mutant clone selection under tumor-imposed pressure, and outline strategies to minimize diagnostic errors in circulating tumor DNA analysis. Metastatic colorectal cancer acts as a systemic regulator of hematopoiesis. Chronic systemic inflammation induced by the secretion of tumor and metastasis mediators (interleukin (IL) 6, tumor necrosis factor α, granulocyte colony-stimulating factor), in combination with persistent oxidative stress, causes replicative exhaustion and apoptosis of normal hematopoietic stem cells. Under these conditions, CHIP clones carrying mutations in genes involved in epigenetic control (TET2, DNMT3A) and DNA damage response (TP53, PPM1D) acquire a selective fitness advantage. In the context of bidirectional regulation, hyperreactive myeloid cells originating from CHIP clones migrate to intestinal and hepatic tissues, where they establish pre-metastatic niches, promote angiogenesis (via vascular endothelial growth factor, matrix metallopeptidase 9), and suppress CD8+ T-cell activity (through programmed death ligand 1, indoleamine-2,3-dioxygenase). Standard platinum-based chemotherapy (FOLFOX) acts as an additional catalyst for the iatrogenic selection of TP53/PPM1D clones, whereas primary tumor resection de-escalates the inflammatory pressure on the bone marrow. CHIP compromises the specificity of liquid biopsy by generating false-positive signals for progression (TP53) and resistance (RAS) markers. The gold standard for overcoming this interference is paired buffy coat sequencing combined with fragmentomics-based approaches. Disruption of the pathological “mCRC ↔ CHIP” axis through anti-cytokine therapy (IL-1β and IL-6 inhibitors) and the integration of onco-hematological monitoring into precision oncology may prevent tumor immune evasion, reduce the risk of secondary leukemias, and improve patient survival outcomes.
- Open Access
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 118-125
Retroperitoneal end colostomy for prevention of parastomal hernia: single-center retrospective study
Background. Retroperitoneal end colostomy creation is a safe and effective method of parastomal hernia (PH) prevention. Aim. To investigate the rate of PH in patients after abdominoperineal resection of the rectum. To compare effects of retroperitoneal end colostomy created through laparoscopic and open accesses on PH prevention. Materials and methods. In the single-center study, incidence of PH was retrospectively analyzed in 110 patients who underwent abdominoperineal resection of the rectum between January of 2018 and December of 2024 due to rectal cancer, persistent or recurrent squamous cell carcinoma of the anal canal after chemoradiation therapy. PH was diagnosed using computed tomography with independent evaluation by an expert 1 or more years after the surgery. Patient characteristics, PH incidence, rate and severity of postoperative complications were compared in the groups of laparoscopic and open surgeries. Results. Median follow-up was 19.2 months in the group of extraperitoneal colostomy and 12.8 months in the group of transperitoneal colostomy. Statistically significant differences (р = 0.027) were found in the incidence of hernias 1 and more years after surgery in the laparoscopic surgery group: hernias developed in 5 (14.3 %; 95 % confidence interval (CI) 48–29.8) patients with extraperitoneal colostomy and in 10 (40 %; 95 % CI 21.1–61.2) patients with transperitoneal colostomy. There were no significant differences in the rate of adverse events (р = 0.76). In the total group and group of open surgeries, no statistically significant differences were observed (р = 0.146): hernias developed in 10 (17.9 %; 95 % CI 8.8–30.5) patients with extraperitoneal colostomy and 16 (29.6 %; 95 % CI 17.9–42.4) patients with transperitoneal colostomy in the total group, in 5 (22.7 %; 95 % CI 8.3–45.4) patients with extraperitoneal stoma, and in 6 (20.7 %; 95 % CI 8.4–39.5) patients with transperitoneal stoma in the open surgery group. Conclusion. The results of our study do not demonstrate benefits of extraperitoneal colostomy using open access. However, the results show safety and efficacy of retroperitoneal end colostomy creation in laparoscopic abdominoperineal resection.
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 118-125
Open AccessRetroperitoneal end colostomy for prevention of parastomal hernia: single-center retrospective study
Background. Retroperitoneal end colostomy creation is a safe and effective method of parastomal hernia (PH) prevention. Aim. To investigate the rate of PH in patients after abdominoperineal resection of the rectum. To compare effects of retroperitoneal end colostomy created through laparoscopic and open accesses on PH prevention. Materials and methods. In the single-center study, incidence of PH was retrospectively analyzed in 110 patients who underwent abdominoperineal resection of the rectum between January of 2018 and December of 2024 due to rectal cancer, persistent or recurrent squamous cell carcinoma of the anal canal after chemoradiation therapy. PH was diagnosed using computed tomography with independent evaluation by an expert 1 or more years after the surgery. Patient characteristics, PH incidence, rate and severity of postoperative complications were compared in the groups of laparoscopic and open surgeries. Results. Median follow-up was 19.2 months in the group of extraperitoneal colostomy and 12.8 months in the group of transperitoneal colostomy. Statistically significant differences (р = 0.027) were found in the incidence of hernias 1 and more years after surgery in the laparoscopic surgery group: hernias developed in 5 (14.3 %; 95 % confidence interval (CI) 48–29.8) patients with extraperitoneal colostomy and in 10 (40 %; 95 % CI 21.1–61.2) patients with transperitoneal colostomy. There were no significant differences in the rate of adverse events (р = 0.76). In the total group and group of open surgeries, no statistically significant differences were observed (р = 0.146): hernias developed in 10 (17.9 %; 95 % CI 8.8–30.5) patients with extraperitoneal colostomy and 16 (29.6 %; 95 % CI 17.9–42.4) patients with transperitoneal colostomy in the total group, in 5 (22.7 %; 95 % CI 8.3–45.4) patients with extraperitoneal stoma, and in 6 (20.7 %; 95 % CI 8.4–39.5) patients with transperitoneal stoma in the open surgery group. Conclusion. The results of our study do not demonstrate benefits of extraperitoneal colostomy using open access. However, the results show safety and efficacy of retroperitoneal end colostomy creation in laparoscopic abdominoperineal resection.
- Open Access
- 8 April 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (1) , 75-82
Bowel resection in cytoreductive surgery for advanced ovarian cancer: incidence of complications and impact on timing of adjuvant chemotherapy. A retrospective study
Background. Cytoreductive surgery is the mainstay of treatment for patients with advanced ovarian cancer (AOC). Bowel resection is often required to achieve complete cytoreductive surgery. However, such interventions are associated with an increased risk of postoperative complications, which may affect the timing of adjuvant chemotherapy and long-term oncological outcomes. Aim. To assess the frequency and structure of postoperative complications in patients with AOC who underwent cytoreductive surgery with bowel resection, and to analyze their impact on the timing of chemotherapy initiation, relapse-free and overall survival. Materials and methods. A retrospective study was conducted on 67 patients with stage IIB–IV ovarian cancer who underwent cytoreductive surgery, including bowel resection, at the Blokhin National Medical Research Center of Oncology from 2018 to 2023. The incidence of complications was assessed using the Clavien–Dindo classification. The impact of complications and timing of chemotherapy initiation on overall and relapse-free survival was studied using the Kaplan–Meier method with the Log-rank test. Results. Postoperative complications were registered in 10.4% of patients; severe (III–IV according to Clavien–Dindo) – in 6%. The median time before the start of chemotherapy was 21 days; in 42% of patients, treatment was started after 21 days. Relapse-free survival after 3 years was about 50%, the overall 5-year survival was 71%. Differences in relapse-free and overall survival between subgroups (with and without complications; with and without delayed chemotherapy) did not reach statistical significance (p 0.1), but there was a tendency for survival to decrease in the presence of complications. Conclusion. Bowel resection as part of operations for AOC provides an increase in the frequency of achieving complete and optimal cytoreduction with an acceptable complication rate. Despite some prolongation of the timing of the start of chemotherapy in case of complications, no statistically significant deterioration in long-term results was recorded. The data obtained confirm the justification of a more aggressive surgical approach with adequate postoperative management of patients.
- 8 April 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (1) , 75-82
Open AccessBowel resection in cytoreductive surgery for advanced ovarian cancer: incidence of complications and impact on timing of adjuvant chemotherapy. A retrospective study
Background. Cytoreductive surgery is the mainstay of treatment for patients with advanced ovarian cancer (AOC). Bowel resection is often required to achieve complete cytoreductive surgery. However, such interventions are associated with an increased risk of postoperative complications, which may affect the timing of adjuvant chemotherapy and long-term oncological outcomes. Aim. To assess the frequency and structure of postoperative complications in patients with AOC who underwent cytoreductive surgery with bowel resection, and to analyze their impact on the timing of chemotherapy initiation, relapse-free and overall survival. Materials and methods. A retrospective study was conducted on 67 patients with stage IIB–IV ovarian cancer who underwent cytoreductive surgery, including bowel resection, at the Blokhin National Medical Research Center of Oncology from 2018 to 2023. The incidence of complications was assessed using the Clavien–Dindo classification. The impact of complications and timing of chemotherapy initiation on overall and relapse-free survival was studied using the Kaplan–Meier method with the Log-rank test. Results. Postoperative complications were registered in 10.4% of patients; severe (III–IV according to Clavien–Dindo) – in 6%. The median time before the start of chemotherapy was 21 days; in 42% of patients, treatment was started after 21 days. Relapse-free survival after 3 years was about 50%, the overall 5-year survival was 71%. Differences in relapse-free and overall survival between subgroups (with and without complications; with and without delayed chemotherapy) did not reach statistical significance (p 0.1), but there was a tendency for survival to decrease in the presence of complications. Conclusion. Bowel resection as part of operations for AOC provides an increase in the frequency of achieving complete and optimal cytoreduction with an acceptable complication rate. Despite some prolongation of the timing of the start of chemotherapy in case of complications, no statistically significant deterioration in long-term results was recorded. The data obtained confirm the justification of a more aggressive surgical approach with adequate postoperative management of patients.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500602
Neoadjuvant Immunotherapy With Prolgolimab in Patients With Locally Advanced Microsatellite Instability/Defective Mismatch Repair Colorectal Cancer
PURPOSE: Although adjuvant chemotherapy is standard for locally advanced colon cancer, defective mismatch repair (dMMR)/microsatellite instability (MSI) tumors show high sensitivity to immune checkpoint inhibitors. We aimed to investigate the efficacy of the PD-1 inhibitor prolgolimab in this setting. METHODS: We conducted phase II nonrandomized open-label clinical trial (ClinicalTrials.gov identifier: NCT06428487 ) in patients with locally advanced colorectal cancer (CRC) and dMMR/MSI. Prolgolimab (1 mg/kg) was administered once every 2 weeks, and surgery was performed after 6 months of immunotherapy. In case of surgical treatment refusal, the systemic treatment proceeded for 1 year. The primary end point was the rate of pathologic complete response (pCR, in operated cases) + clinical complete response (cCR, in nonoperated cases). Secondary end points included pCR, major pathologic response (MPR), objective response (ORR) rates, safety, disease-free survival (DFS), and overall survival. RESULTS: Of the 30 enrolled, 26 (86.6%) patients underwent surgery after the end of immunotherapy. The study met its primary end point, with 17 (56.7%) of 30 patients achieving pCR (n = 16) + cCR (n = 1 as nonoperated case). According to histologic examination, an MPR (TRG 1-2) was observed in 21 (80.8%) of 26 patients, including 16 (61.6%) patients with pCR. Radiographic ORR was 89.7%, and cCR was observed in six cases (20.7%, five patients underwent surgery further). Three patients with low rectal primary tumors refused to undergo a surgical treatment. The median follow-up was 19 months (range, 13-32). The 18-month DFS was 90%: two progressions and one unrelated death were detected. Grade 3-4 immune-related adverse effects were recorded in one (3.3%) patient. CONCLUSION: The use of prolgolimab in locally advanced dMMR/MSI CRC is associated with high rates of pCR and cCR, allowing for further exploration of organ-sparing approaches in these patients.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500602
Neoadjuvant Immunotherapy With Prolgolimab in Patients With Locally Advanced Microsatellite Instability/Defective Mismatch Repair Colorectal Cancer
PURPOSE: Although adjuvant chemotherapy is standard for locally advanced colon cancer, defective mismatch repair (dMMR)/microsatellite instability (MSI) tumors show high sensitivity to immune checkpoint inhibitors. We aimed to investigate the efficacy of the PD-1 inhibitor prolgolimab in this setting. METHODS: We conducted phase II nonrandomized open-label clinical trial (ClinicalTrials.gov identifier: NCT06428487 ) in patients with locally advanced colorectal cancer (CRC) and dMMR/MSI. Prolgolimab (1 mg/kg) was administered once every 2 weeks, and surgery was performed after 6 months of immunotherapy. In case of surgical treatment refusal, the systemic treatment proceeded for 1 year. The primary end point was the rate of pathologic complete response (pCR, in operated cases) + clinical complete response (cCR, in nonoperated cases). Secondary end points included pCR, major pathologic response (MPR), objective response (ORR) rates, safety, disease-free survival (DFS), and overall survival. RESULTS: Of the 30 enrolled, 26 (86.6%) patients underwent surgery after the end of immunotherapy. The study met its primary end point, with 17 (56.7%) of 30 patients achieving pCR (n = 16) + cCR (n = 1 as nonoperated case). According to histologic examination, an MPR (TRG 1-2) was observed in 21 (80.8%) of 26 patients, including 16 (61.6%) patients with pCR. Radiographic ORR was 89.7%, and cCR was observed in six cases (20.7%, five patients underwent surgery further). Three patients with low rectal primary tumors refused to undergo a surgical treatment. The median follow-up was 19 months (range, 13-32). The 18-month DFS was 90%: two progressions and one unrelated death were detected. Grade 3-4 immune-related adverse effects were recorded in one (3.3%) patient. CONCLUSION: The use of prolgolimab in locally advanced dMMR/MSI CRC is associated with high rates of pCR and cCR, allowing for further exploration of organ-sparing approaches in these patients.
- Open Access
- 20 March 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (1) , 18-27
Three-year results of the Russian multicenter prospective randomized trial RuCort3
Background. The development of local recurrences and distant metastases make the problem of treating locally advanced rectal cancer one of the main problems in modern oncoproctology. The organ-preserving approach, sphincter-preserving operations, the role of a complete clinical response to therapy and the low compliance of patients with adjuvant treatment remain in the focus of attention of scientists.Aim. Evaluation of the effectiveness of neoadjuvant sequential induction chemotherapy (CT), chemoradiotherapy (CRT), and CapOx consolidating chemotherapy in patients with locally advanced rectal cancer.Methods. From December 2019 to June 2024, an open-label, randomized phase III study enrolled patients with locally advanced rectal cancer from 3 centers. The inclusion criteria for patients in the study were: histologically confirmed adenocarcinoma, lower and middle rectal cancer, magnetic resonance imaging on a Tesla 3 machine CRM+/4N0-2M0, age 18–75 years, ECOG performance status 0–1. Patients were divided into 2 groups: in the study group, treatment began with 2 courses of induction CT according to the CapOx regimen (oxaliplatin 130 mg/m2 on the 1st day of the course intravenously by drip, capecitabine 2000 mg/m2 twice a day at 12-hour intervals for 14 days, 7 days break). Then, a long course of chemoradiotherapy was carried out: 44 Gy to the areas of regional metastasis, 50–54 Gy to the primary tumor against the background of CT with capecitabine 825 mg/m2 2 times a day per os on the days of radiation therapy. One to two weeks after the end of CRT, two more courses of consolidation CT were carried out according to the CapOx scheme. A control examination was performed 10–12 weeks after the end of CRT. In the control group, a prolonged course of CRT was carried out: ROD 2 Gy, SOD 44 Gy to the areas of regional metastasis and SOD 50–54 Gy to the primary tumor against the background of CT with capecitabine 825 mg/m2 2 times a day per os on the days of radiation therapy. The primary endpoint was 3-year disease-free survival, calculated from the start of treatment to the date of progression and/or death from any cause or the date of last follow-up. Situations when a patient did not die and did not have disease progression were considered as censored events. Survival was calculated using the Kaplan–Meier method.Results. 247 patients were included in the study, 178 (72.1 %) underwent a complete course of treatment, 12 (4.9 %) patients are in the process of treatment or waiting for surgery, 25 (10.1 %) patients were excluded from the study for various reasons: organizational problems, refusal of treatment after randomization, detection of a synchronous tumor or metastases before starting treatment. The remaining 32 (12.9 %) patients did not follow the planned treatment protocol due to progression, death or refusal to continue treatment. The prevalence of acute grade III–V toxicities during preoperative treatment was 6.8 % in the CRT + CT group versus 4.7 % in the CRT group. 19 patients with a complete clinical response refused surgical treatment. 6 (5.8 %) patients in the CRT group and 13 (12.1 %) patients from the group in the CRT + CT group (p = 0.05). The disease free median duration of follow-up in group complete clinical response was 1086 days (36.2 months). Sphincter-sparing operations in the CRT + CT group were performed in 54 (65.8 %) patients versus 41 (53.2 %) in the CRT group (p = 0.05). A subgroup analysis of patients with low rectal cancer showed a significant increase in the frequency of sphincter preservation operations in the main group – 23 (46.9 %) versus 16 (31.4 %) in the control group (p = 0.05). On the basis of the Clavien–Dindo classification, the prevalence of surgical complications was similar between the two groups. The total rate of pCR in the CRT + CT group was 41.2 %, which was significantly higher than that in the CRT group (29.8 %). We demonstrated that patients receiving CRT with neoadjuvant CT were well tolerated, with a compliance rate of 71.2 % than those received adjuvant CT (31.2 %, p = 0.05). In particular, 95 % of the patients in the main group underwent 4 planned courses of neoadjuvant CT. 32.5 % of patients in the chemoradiotherapy group did not start adjuvant CT versus 16 % in the study group. The median duration of follow-up was 36 month. Locoregional recurrence was observed in 5 patients: 3 (2.8 %) in the CRT + CT group (1 patient was operated in a non-specialized clinic, after completion of preoperative treatment within the protocol) and 2 (1.9 %) in the CRT group. There was no significant difference in distant metastases: 20 (19.2 %) patients in CRT group and 21 (19.6 %) patients in the study group. There was no significant difference in dieseas-free survival (75 % in the CRT group versus 77 % in the CRT + CT group). Conclusion. Chemoradiotherapy with preoperative CT followed by surgery was efficacious for locally advanced rectal cancer with a significant increase frequency complete clinical response, sphincter-preserving operations, organpreserving treatment including low rectal cancer and rate patient compliance with CT.
- 20 March 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (1) , 18-27
Open AccessThree-year results of the Russian multicenter prospective randomized trial RuCort3
Background. The development of local recurrences and distant metastases make the problem of treating locally advanced rectal cancer one of the main problems in modern oncoproctology. The organ-preserving approach, sphincter-preserving operations, the role of a complete clinical response to therapy and the low compliance of patients with adjuvant treatment remain in the focus of attention of scientists.Aim. Evaluation of the effectiveness of neoadjuvant sequential induction chemotherapy (CT), chemoradiotherapy (CRT), and CapOx consolidating chemotherapy in patients with locally advanced rectal cancer.Methods. From December 2019 to June 2024, an open-label, randomized phase III study enrolled patients with locally advanced rectal cancer from 3 centers. The inclusion criteria for patients in the study were: histologically confirmed adenocarcinoma, lower and middle rectal cancer, magnetic resonance imaging on a Tesla 3 machine CRM+/4N0-2M0, age 18–75 years, ECOG performance status 0–1. Patients were divided into 2 groups: in the study group, treatment began with 2 courses of induction CT according to the CapOx regimen (oxaliplatin 130 mg/m2 on the 1st day of the course intravenously by drip, capecitabine 2000 mg/m2 twice a day at 12-hour intervals for 14 days, 7 days break). Then, a long course of chemoradiotherapy was carried out: 44 Gy to the areas of regional metastasis, 50–54 Gy to the primary tumor against the background of CT with capecitabine 825 mg/m2 2 times a day per os on the days of radiation therapy. One to two weeks after the end of CRT, two more courses of consolidation CT were carried out according to the CapOx scheme. A control examination was performed 10–12 weeks after the end of CRT. In the control group, a prolonged course of CRT was carried out: ROD 2 Gy, SOD 44 Gy to the areas of regional metastasis and SOD 50–54 Gy to the primary tumor against the background of CT with capecitabine 825 mg/m2 2 times a day per os on the days of radiation therapy. The primary endpoint was 3-year disease-free survival, calculated from the start of treatment to the date of progression and/or death from any cause or the date of last follow-up. Situations when a patient did not die and did not have disease progression were considered as censored events. Survival was calculated using the Kaplan–Meier method.Results. 247 patients were included in the study, 178 (72.1 %) underwent a complete course of treatment, 12 (4.9 %) patients are in the process of treatment or waiting for surgery, 25 (10.1 %) patients were excluded from the study for various reasons: organizational problems, refusal of treatment after randomization, detection of a synchronous tumor or metastases before starting treatment. The remaining 32 (12.9 %) patients did not follow the planned treatment protocol due to progression, death or refusal to continue treatment. The prevalence of acute grade III–V toxicities during preoperative treatment was 6.8 % in the CRT + CT group versus 4.7 % in the CRT group. 19 patients with a complete clinical response refused surgical treatment. 6 (5.8 %) patients in the CRT group and 13 (12.1 %) patients from the group in the CRT + CT group (p = 0.05). The disease free median duration of follow-up in group complete clinical response was 1086 days (36.2 months). Sphincter-sparing operations in the CRT + CT group were performed in 54 (65.8 %) patients versus 41 (53.2 %) in the CRT group (p = 0.05). A subgroup analysis of patients with low rectal cancer showed a significant increase in the frequency of sphincter preservation operations in the main group – 23 (46.9 %) versus 16 (31.4 %) in the control group (p = 0.05). On the basis of the Clavien–Dindo classification, the prevalence of surgical complications was similar between the two groups. The total rate of pCR in the CRT + CT group was 41.2 %, which was significantly higher than that in the CRT group (29.8 %). We demonstrated that patients receiving CRT with neoadjuvant CT were well tolerated, with a compliance rate of 71.2 % than those received adjuvant CT (31.2 %, p = 0.05). In particular, 95 % of the patients in the main group underwent 4 planned courses of neoadjuvant CT. 32.5 % of patients in the chemoradiotherapy group did not start adjuvant CT versus 16 % in the study group. The median duration of follow-up was 36 month. Locoregional recurrence was observed in 5 patients: 3 (2.8 %) in the CRT + CT group (1 patient was operated in a non-specialized clinic, after completion of preoperative treatment within the protocol) and 2 (1.9 %) in the CRT group. There was no significant difference in distant metastases: 20 (19.2 %) patients in CRT group and 21 (19.6 %) patients in the study group. There was no significant difference in dieseas-free survival (75 % in the CRT group versus 77 % in the CRT + CT group). Conclusion. Chemoradiotherapy with preoperative CT followed by surgery was efficacious for locally advanced rectal cancer with a significant increase frequency complete clinical response, sphincter-preserving operations, organpreserving treatment including low rectal cancer and rate patient compliance with CT.
- Open Access
- 20 March 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (1) , 36-41
Distal resection margin in colorectal surgery in vivo and after formalin fixation
Introduction. Historically, the standard for distal margin in rectal cancer surgery has been the 5 cm «rule». Currently, there is a trend to reduction the distal surgical margin. However, intraoperative specimen measurements and histological examination data differ. The phenomenon of surgical shrinkage plays a significant role, especially in determining the distal resection margin, as intraoperative data may not coincide with measurement after fixation of the specimen. Possible differences may lead to doubts about the oncological adequacy of the performed resection boundaries.Aim. To examine the shrinkage effect of distal resection margin in colorectal cancer after organ formalin fixation.Materials and methods. The prospective analysis included data of 20 patients with histologically confirmed rectal cancer and sigmoid cancer (adenocarcinoma G1–3) for whom surgical treatment is recommended. The distance between the lower edge of tumor to the distal resection margin was measured after resection (in vivo) and after 5–12 minutes after the last measurement. Then the determination of this distance was made after formalin fixation (in vitro).Results. The analysis revealed that the average shrinkage of the distal resection margin from in vivo to ex vivo was 30.5 mm (25,5 %) (p = 0.0001). The average shrinkage between in vivo and in vitro bowel samples was 51.0 mm.Conclusions. Measurement of the distal resection margin under different conditions influences the estimation of the oncological clearence in interpreting the results of pathological report and determining the results of treatment.
- 20 March 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (1) , 36-41
Open AccessDistal resection margin in colorectal surgery in vivo and after formalin fixation
Introduction. Historically, the standard for distal margin in rectal cancer surgery has been the 5 cm «rule». Currently, there is a trend to reduction the distal surgical margin. However, intraoperative specimen measurements and histological examination data differ. The phenomenon of surgical shrinkage plays a significant role, especially in determining the distal resection margin, as intraoperative data may not coincide with measurement after fixation of the specimen. Possible differences may lead to doubts about the oncological adequacy of the performed resection boundaries.Aim. To examine the shrinkage effect of distal resection margin in colorectal cancer after organ formalin fixation.Materials and methods. The prospective analysis included data of 20 patients with histologically confirmed rectal cancer and sigmoid cancer (adenocarcinoma G1–3) for whom surgical treatment is recommended. The distance between the lower edge of tumor to the distal resection margin was measured after resection (in vivo) and after 5–12 minutes after the last measurement. Then the determination of this distance was made after formalin fixation (in vitro).Results. The analysis revealed that the average shrinkage of the distal resection margin from in vivo to ex vivo was 30.5 mm (25,5 %) (p = 0.0001). The average shrinkage between in vivo and in vitro bowel samples was 51.0 mm.Conclusions. Measurement of the distal resection margin under different conditions influences the estimation of the oncological clearence in interpreting the results of pathological report and determining the results of treatment.
- Open Access
- 22 July 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (2) , 65-74
Total neoadjuvant therapy for locally advanced rectal cancer: a literature review
The problem of locally advanced rectal cancer (LARC) treatment has not lost its importance and relevance over the past decades, due to the steady increase in the incidence. For a long time, neoadjuvant chemoradiotherapy (nCRT) before total mesorectal excision (TME) and followed systemic chemotherapy was widely accepted as the standard therapy for locally advanced rectal cancer. Although local control is more than satisfactory using this approach, the same cannot be said of distant metastases, which rate reaches 30 % or more and is mainly the cause of death of this category of patients. One of the reasons for this lack of improvement may be the rate of patients who complete the planned adjuvant chemotherapy, which is approximately 50 %. The reasons for that may be postoperative complications, long-term recovery after extensive surgical procedures, etc. Total Neoadjuvant Therapy (TNT) is an emerging approach for the treatment of LARC aimed at improving distant metastasis. This review will outline the main steps in the evolution of LARC treatment and the formation of the stages of total neoadjuvant therapy.
- 22 July 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (2) , 65-74
Open AccessTotal neoadjuvant therapy for locally advanced rectal cancer: a literature review
The problem of locally advanced rectal cancer (LARC) treatment has not lost its importance and relevance over the past decades, due to the steady increase in the incidence. For a long time, neoadjuvant chemoradiotherapy (nCRT) before total mesorectal excision (TME) and followed systemic chemotherapy was widely accepted as the standard therapy for locally advanced rectal cancer. Although local control is more than satisfactory using this approach, the same cannot be said of distant metastases, which rate reaches 30 % or more and is mainly the cause of death of this category of patients. One of the reasons for this lack of improvement may be the rate of patients who complete the planned adjuvant chemotherapy, which is approximately 50 %. The reasons for that may be postoperative complications, long-term recovery after extensive surgical procedures, etc. Total Neoadjuvant Therapy (TNT) is an emerging approach for the treatment of LARC aimed at improving distant metastasis. This review will outline the main steps in the evolution of LARC treatment and the formation of the stages of total neoadjuvant therapy.
- Open Access
- 21 July 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (2) , 19-28
Interim results of neoadjuvant immunotherapy with prolgolimab in patients with locally advanced MSI / dMMR colorectal cancer
Introduction: Colorectal cancer is one of the leading malignancies in Russia [1]. The standard approach for selected patients (pts) with locally advanced colon cancer is surgery with adjuvant chemotherapy. Several studies have shown that colorectal cancer (CRC) with presence of a disorder in the mismatch repair (dMMR) / microsatellite instability (MSI) is characterized with high sensitivity to the immune checkpoint inhibitors. Several studies have shown that MSI / dMMR CRC patients tend to be more responsive to immune checkpoint inhibitors such as pembrolizumab, nivolumab or ipilimumab. However, there was no information about the efficacy of prolgolimab, a PD-1 receptor blocking antibody. Prolgolimab was highly effective in melanoma treatment, while the toxicity was comparable to pembrolizumab and nivolumab. Methods: We initiated the phase II non-randomized open-label clinical trial. Inclusion criteria were: histologically verified, MSI / dMMR, clinical stage II–III CRC. According to study protocol, prolgolimab (1 mg / kg) is administered every two weeks, then surgery should be done after 6 months of immunotherapy (12 cycles). In case of surgical treatment refusal, the systemic treatment proceeds for 1 year. The co-primary endpoint was the complete response (pCR) rate. Secondary endpoints included tumor regression grade by Mandard (TRG), major pathologic response (MPR), overall response rate (ORR) disease free survival (DFS) and overall survival (OS). Here is a presentation of safety and pathologic response data — rates of pCR / MPR, objective response rate. Results: A total of 26 patients began treatment with prolgolimab from April, 2022 to February, 2024. Immune-related adverse effects of grade III–IV, were recorded in 1 (3,8 %) patient (autoimmune hepatitis grade IV); 4 (15,4 %) patients had adverse effects grade I–II: autoimmune thyroiditis, diarrhea, hypothyroidism. Two patients were refused to make a surgical treatment because of clinical CR and possible volume of surgery. Nine (34,6 %) patients underwent surgical treatment within 3 months after the immunotherapy completion: 7 patients had TRG 1 and pCR, 2 — TRG 2 and MPR after the treatment. ORR was 100 %, complete clinical response rate 40 %. The study is still ongoing, DFS and OS will be announced in further publications. Median follow-up time was 5 months. Conclusion: The first interim analysis data suggest a strong potential for neoadjuvant immunotherapy to become standard of care and allow further exploration of organ-sparing approaches in MMR / MSI CRC patients.
- 21 July 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (2) , 19-28
Open AccessInterim results of neoadjuvant immunotherapy with prolgolimab in patients with locally advanced MSI / dMMR colorectal cancer
Introduction: Colorectal cancer is one of the leading malignancies in Russia [1]. The standard approach for selected patients (pts) with locally advanced colon cancer is surgery with adjuvant chemotherapy. Several studies have shown that colorectal cancer (CRC) with presence of a disorder in the mismatch repair (dMMR) / microsatellite instability (MSI) is characterized with high sensitivity to the immune checkpoint inhibitors. Several studies have shown that MSI / dMMR CRC patients tend to be more responsive to immune checkpoint inhibitors such as pembrolizumab, nivolumab or ipilimumab. However, there was no information about the efficacy of prolgolimab, a PD-1 receptor blocking antibody. Prolgolimab was highly effective in melanoma treatment, while the toxicity was comparable to pembrolizumab and nivolumab. Methods: We initiated the phase II non-randomized open-label clinical trial. Inclusion criteria were: histologically verified, MSI / dMMR, clinical stage II–III CRC. According to study protocol, prolgolimab (1 mg / kg) is administered every two weeks, then surgery should be done after 6 months of immunotherapy (12 cycles). In case of surgical treatment refusal, the systemic treatment proceeds for 1 year. The co-primary endpoint was the complete response (pCR) rate. Secondary endpoints included tumor regression grade by Mandard (TRG), major pathologic response (MPR), overall response rate (ORR) disease free survival (DFS) and overall survival (OS). Here is a presentation of safety and pathologic response data — rates of pCR / MPR, objective response rate. Results: A total of 26 patients began treatment with prolgolimab from April, 2022 to February, 2024. Immune-related adverse effects of grade III–IV, were recorded in 1 (3,8 %) patient (autoimmune hepatitis grade IV); 4 (15,4 %) patients had adverse effects grade I–II: autoimmune thyroiditis, diarrhea, hypothyroidism. Two patients were refused to make a surgical treatment because of clinical CR and possible volume of surgery. Nine (34,6 %) patients underwent surgical treatment within 3 months after the immunotherapy completion: 7 patients had TRG 1 and pCR, 2 — TRG 2 and MPR after the treatment. ORR was 100 %, complete clinical response rate 40 %. The study is still ongoing, DFS and OS will be announced in further publications. Median follow-up time was 5 months. Conclusion: The first interim analysis data suggest a strong potential for neoadjuvant immunotherapy to become standard of care and allow further exploration of organ-sparing approaches in MMR / MSI CRC patients.
- Open Access
- 7 June 2024
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 14 (2) , 33-37
Positional neuropathies in surgical oncology
Aim. To evaluate the frequency and clinical characteristics of positional neuropathies in patients with cancer who underwent surgery.Materials and methods. A retrospective study of medical records of patients undergoing surgical treatment in 2023, who showed signs of secondary neuropathy of the upper and/or lower extremities in the postoperative period. The main analyzed parameter was the frequency of postoperative neuropathies among patients who underwent surgery; additional parameters were the degree of neurological deficit according to the neurological deficit assessment scale, the median regression of neurological deficit. Results. The study included 29 patients who underwent surgery at the National Medical Research Center of Oncology named after N. N. Blokhin in 2023, who developed a clinical picture of positional neuropathy in the postoperative period. The overall incidence of positional neuropathies was 0.28 %. Neuropathies of the brachial plexus were predominant (96 %). A severe degree of neurological deficit was noted in 35 %, medium – in 45 %, mild – in 20 % of patients. 27.5 % of patients continued to have varying degrees of neurological deficit over a 10-month period.Conclusion. Positional neuropathies can persist for a long time; it is necessary to develop methods for their prevention.
- 7 June 2024
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 14 (2) , 33-37
Open AccessPositional neuropathies in surgical oncology
Aim. To evaluate the frequency and clinical characteristics of positional neuropathies in patients with cancer who underwent surgery.Materials and methods. A retrospective study of medical records of patients undergoing surgical treatment in 2023, who showed signs of secondary neuropathy of the upper and/or lower extremities in the postoperative period. The main analyzed parameter was the frequency of postoperative neuropathies among patients who underwent surgery; additional parameters were the degree of neurological deficit according to the neurological deficit assessment scale, the median regression of neurological deficit. Results. The study included 29 patients who underwent surgery at the National Medical Research Center of Oncology named after N. N. Blokhin in 2023, who developed a clinical picture of positional neuropathy in the postoperative period. The overall incidence of positional neuropathies was 0.28 %. Neuropathies of the brachial plexus were predominant (96 %). A severe degree of neurological deficit was noted in 35 %, medium – in 45 %, mild – in 20 % of patients. 27.5 % of patients continued to have varying degrees of neurological deficit over a 10-month period.Conclusion. Positional neuropathies can persist for a long time; it is necessary to develop methods for their prevention.
- Open Access
- 31 August 2023
- Published by Korean Society of Coloproctology in Annals of Coloproctology
- Vol. 39 (4) , 289-300
Total neoadjuvant therapy in rectal cancer: a network meta-analysis of randomized trials
Purpose: To assess the efficacy of total neoadjuvant therapy (TNT) for rectal carcinoma in comparison with conventional chemoradiotherapy (CRT).Methods: A systematic review was performed according to the PRISMA guidelines. A Bayesian network meta-analysis was done using NetMetaXL and WinBUGS. This study was registered in PROSPERO on March 3, 2022 (No. CRD-42022307867).Results: Outcomes of 2,719 patients from 10 randomized trials between 2010 and 2022 were selected. Of these 1,191 (44%) had conventional long-course CRT (50–54 Gy) and capecitabine, 506 (18%) had induction chemotherapy followed by CRT (50–54 Gy) and capecitabine (iTNT), 230 (9%) had long-course CRT (50–54 Gy) followed by consolidation chemotherapy (cTNT), and 792 (29%) undergone modified short-course radiotherapy (25 Gy) with subsequent chemotherapy (mTNT). Total pathologic complete response (pCR) was 20% in the iTNT group, 21% in the mTNT group, 22% in the cTNT group, and 12% in the CRT group. Statistically significant difference in pCR rates was detected when comparing iTNT with CRT (odds ratio [OR], 1.76; 95% credible interval [CrI], 1.06–2.8), mTNT with CRT (OR, 1.90; 95% CrI, 1.25–2.74), and cTNT with CRT groups (OR, 2.54; 95% CrI, 1.26–5.08). No differences were found in R0 resection rates. No significant difference was found in long-term outcomes.Conclusion: The early administration of systemic chemotherapy in the TNT regimen has improved short-term outcomes, though long-term results are underreported. Randomized trials with survival as the endpoint are necessary to evaluate the possible advantages of TNT modes.
- 31 August 2023
- Published by Korean Society of Coloproctology in Annals of Coloproctology
- Vol. 39 (4) , 289-300
Open AccessTotal neoadjuvant therapy in rectal cancer: a network meta-analysis of randomized trials
Purpose: To assess the efficacy of total neoadjuvant therapy (TNT) for rectal carcinoma in comparison with conventional chemoradiotherapy (CRT).Methods: A systematic review was performed according to the PRISMA guidelines. A Bayesian network meta-analysis was done using NetMetaXL and WinBUGS. This study was registered in PROSPERO on March 3, 2022 (No. CRD-42022307867).Results: Outcomes of 2,719 patients from 10 randomized trials between 2010 and 2022 were selected. Of these 1,191 (44%) had conventional long-course CRT (50–54 Gy) and capecitabine, 506 (18%) had induction chemotherapy followed by CRT (50–54 Gy) and capecitabine (iTNT), 230 (9%) had long-course CRT (50–54 Gy) followed by consolidation chemotherapy (cTNT), and 792 (29%) undergone modified short-course radiotherapy (25 Gy) with subsequent chemotherapy (mTNT). Total pathologic complete response (pCR) was 20% in the iTNT group, 21% in the mTNT group, 22% in the cTNT group, and 12% in the CRT group. Statistically significant difference in pCR rates was detected when comparing iTNT with CRT (odds ratio [OR], 1.76; 95% credible interval [CrI], 1.06–2.8), mTNT with CRT (OR, 1.90; 95% CrI, 1.25–2.74), and cTNT with CRT groups (OR, 2.54; 95% CrI, 1.26–5.08). No differences were found in R0 resection rates. No significant difference was found in long-term outcomes.Conclusion: The early administration of systemic chemotherapy in the TNT regimen has improved short-term outcomes, though long-term results are underreported. Randomized trials with survival as the endpoint are necessary to evaluate the possible advantages of TNT modes.